Hesperos’ Human-on-a-Chip® technology earns recognition in a Nature Lab Animal article highlighting advancements in human-relevant, new alternative methods (NAMs) models and publishes new research advancing its sarcopenia-on-a-chip system.
Hesperos and Oriental Yeast Co. form a strategic partnership to expand access to Human-on-a-Chip® services across Asia, accelerating safer, more effective preclinical drug development.
Hesperos and GalenusRx receive $3M NIH grant to study drug-induced dementia using Human-on-a-Chip® systems and improve medication safety for older adults.
Hesperos and Bayer unveil the first Human-on-a-Chip® model replicating stress-induced cognitive decline to advance non-animal CNS drug research.
PRESS RELEASE Key Results from Study First Digital Twin from Organ-on-a-Chip: Hesperos successfully created what’s believed to be the first digital twin derived from an organ-on-a-chip (microphysiological) system.Multi-Organ Human System: The study utilized a multi-organ system … Read More
Key Takeaways Hesperos aims to accelerate the preclinical development of Psilera’s lead compound, PSIL-006, targeting frontotemporal dementia (FTD). Press Release “Our platform offers a unique opportunity to assess the compound’s effects on neural tissues derived from … Read More
PharmaVoice Interviews Hesperos President and CEO on the future of New Approach Methodologies (NAMs)
Highlights PharmaVoice interviewed Michael Shuler, President and Cofounder of Hesperos, and Lawrence Florin, CEO of Hesperos, along with other pharma leaders, about the future of New Approach Methodologies (NAMs) They discussed the recent pronouncements from … Read More